<DOC>
	<DOCNO>NCT00603577</DOCNO>
	<brief_summary>Primary objective : To assess effect xaliproden hydrochloride ( xaliproden ) 1 mg per oral daily rate complete resolution peripheral sensory neuropathy ( PSN ) 6 month , follow randomization , completion oxaliplatin-based adjuvant chemotherapy colon cancer . Secondary objective : - To assess effect xaliproden patient-reported outcome use Functional Assessment Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale ( FACT/GOG NTX-12 subscale ) . - To assess effect xaliproden rate least partial recovery grade &gt; 2 PSN 6 month - To assess effect xaliproden time complete recovery PSN - To evaluate safety profile xaliproden</brief_summary>
	<brief_title>Role Xaliproden Recovery Rate From Severe Neuropathy Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Have complete oxaliplatincontaining chemotherapy regimen post complete surgical removal primary colon tumor later 6 week randomization ; Have Grade ≥ 1 PSN , define NCICTCAE version 3.0 Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 ; Blood test within 14 day prior randomization : ( ) AST ( SGOT ) ALT ( SGPT ) ≤2 x upper limit normal ( ULN ) ; ( b ) serum creatinine ≤1.5 x ULN ; ( c ) HbA1c ≤7 % ; ( ) neutrophils ≥1.5x10^9/L ; ( e ) platelets ≥50x10^9/L ; ( f ) Serum Ddimer within normal limit Preexisting peripheral neuropathy prior treatment oxaliplatin Receiving anticancer treatment History recent ( ≤1 year ) thromboembolic event current clinical evidence thromboembolism Unstable cardiac disease History significant neurological psychiatric disorder include dementia seizure , Active uncontrolled infection Active disseminate intravascular coagulation Other serious underlie medical condition could impair ability patient participate study ; Use antidepressant/antiepileptic medication ( treatment PSN ) , unless commence informed consent form sign . The addition medication ( treatment PSN ) patient consent allowed Concurrent treatment experimental drug Pregnant breastfeed woman ; Women childbearing potential must protect effective contraceptive method birth control . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Those condition assess patient registration trial . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>